It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Celiac disease (CeD) is a common small bowel enteropathy characterized by an altered adaptive immune system and increased mucosal antigen presenting cells. This study aims to establish if quantification of corneal Langerhans cells (LCs) using corneal confocal microscopy (CCM) could act as a surrogate marker for antigen presenting cell status and hence disease activity in children with CeD. Twenty children with stable CeD and 20 age-matched controls underwent CCM and quantification of central corneal total, mature and immature LC density. There was no difference in age (11.78 ± 1.7 vs. 12.83 ± 1.91; P = 0.077) or height (1.38 ± 0.14 vs. 1.44 ± 0.13; P = 0.125). BMI (18.81 ± 3.90 vs. 22.26 ± 5.47; P = 0.031) and 25 OHD levels (43.50 ± 13.36 vs. 59.77 ± 22.45; P = 0.014) were significantly lower in children with CeD compared to controls. The total (33.33(16.67–59.37) vs. 51.56(30.21–85.42); P = 0.343), immature (33.33(16.67–52.08) vs. 44.79(29.17–82.29); P = 0.752) and mature (1.56(0–5) vs. 1.56(1.04–8.33); P = 0.752) LC density did not differ between the CeD and control groups. However, immature (r = 0.535, P = 0.015), mature (r = 0.464, P = 0.039), and total (r = 0.548, P = 0.012) LC density correlated with age. Immature (r = 0.602, P = 0.038) and total (r = 0.637, P = 0.026) LC density also correlated with tissue transglutaminase antibody (Anti-TtG) levels assessed in 12/20 subjects with CeD. There was no difference in corneal LC density between children with CeD and controls. However, the correlation between corneal LC density and anti-TtG levels suggests a relationship with disease activity in CeD and requires further study.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Weill Cornell Medicine-Qatar, Department Medicine, Doha, Qatar (GRID:grid.416973.e) (ISNI:0000 0004 0582 4340)
2 Albany Medical Center Hospital, Department of Internal Medicine, Albany, USA (GRID:grid.413558.e) (ISNI:0000 0001 0427 8745)
3 Sidra Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Doha, Qatar (GRID:grid.467063.0) (ISNI:0000 0004 0397 4222)
4 University of Manchester, Institute of Cardiovascular Medicine, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
5 Khyber Medical University, Faculty of Health Sciences, Peshawar, Pakistan (GRID:grid.444779.d) (ISNI:0000 0004 0447 5097)
6 Sidra Medicine, Research Department, Doha, Qatar (GRID:grid.467063.0) (ISNI:0000 0004 0397 4222)
7 Sidra Medicine, Division of Endocrinology, Doha, Qatar (GRID:grid.467063.0) (ISNI:0000 0004 0397 4222)
8 Sidra Medicine, General Pediatrics Department, Doha, Qatar (GRID:grid.467063.0) (ISNI:0000 0004 0397 4222)
9 Weill Cornell Medicine-Qatar, Department Medicine, Doha, Qatar (GRID:grid.416973.e) (ISNI:0000 0004 0582 4340); University of Manchester, Institute of Cardiovascular Medicine, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)